ArticleTargeted oncology2024

Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).

Naoya Nishioka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.